Latest Security News

US Masters Residential Property Group reports a half-year profit and advances its ambitious asset sales program, while navigating a significant US tax structure change and mixed market conditions.

Global Health Limited reports solid progress towards profitability in FY2025, driven by a 6% increase in subscription revenue and strategic AI integration across its healthcare platforms.

Electro Optic Systems (EOS) has secured a role in the Australian Defence Force’s $1.3 billion Project LAND 156, aiming to develop advanced counter-drone capabilities over the next decade. Initial orders for EOS’s Slinger remote weapon system could boost revenues from 2026 onwards.

Global Health Limited reported a reduced net loss for FY2025, driven by growing subscription revenue and strategic AI integration as it transitions to a SaaS platform.

humm Group has disclosed the key terms of CEO Angelo Demasi’s employment agreement, highlighting a $750,000 salary and significant incentive opportunities tied to company performance.

Nutritional Growth Solutions has settled to exit non-core US agreements, unlocking nearly $580,000 in financial relief and streamlining its strategic focus.

N1 Holdings reported a 6.8% revenue increase to $19.69 million for FY25, while net profit fell 21.1% to $855,826. The company advanced AI initiatives and expanded lending capacity, signaling strategic growth despite profit pressures.

Optiscan Imaging Limited has launched a $17.75 million fully underwritten entitlement offer to fund clinical trials, regulatory approvals, and product development. Peters Investments underwrites the offer, potentially increasing its stake to nearly 39%.

betr Entertainment Limited has removed a key condition from its takeover offer for PointsBet Holdings, clearing a significant hurdle in the acquisition process. The move signals increased confidence in completing the deal and reshapes the dynamics for PointsBet shareholders and employees.

Cedar Woods Properties has updated its Dividend Reinvestment Plan default to cash payment and announced a fully franked 19-cent dividend for the half-year ending June 2025.

Cambium Bio has updated its placement, raising A$2.17 million to fund late-stage clinical trials for its lead ophthalmology product, Elate Ocular®. The capital raise reflects strong investor interest and strategic backing.

Optiscan Imaging Ltd has launched a fully underwritten $17.75 million entitlement offer to fund clinical trials and regulatory clearances for its medical devices, marking a pivotal step in its transition to a commercial medical device manufacturer.